CSF (VictoryShares US Discovery Enhanced Volatility Wtd ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.

The VictoryShares US Discovery Enhanced Volatility Wtd ETF seeks to provide investment results that track the performance of the Nasdaq VictoryUS Small Cap 500 Long/Cash Volatility Weighted Index (the “Long/Cash Index”) before fees and expenses. Volatility Weighting Methodology Combines fundamental criteria and volatility weighting in an effort to outperform traditional cap-weighted indexing strategies. About the Long/Cash Index The Long/Cash Index tactically reduces its exposure to the equity markets during periods of significant market declines and reinvests when market prices have further…
Is CSF's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with

SAN FRANCISCO--(BUSINESS WIRE)--Chime® (Nasdaq: CHYM), America's #1 choice for banking1, today announced its 2026–2027 Chime Scholars Foundation® (CSF) cohort, awarding $3 million in scholarships to 800 students across the country. Chime launched CSF in 2022 to expand access to higher education by easing financial burdens, boosting graduation rates, and opening doors to careers that pay more. Now in its fifth year, CSF has awarded close to $10 million in scholarships, supporting nearly 1,500 st.

Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells alongside tumor-derived DNA and broaden the leptomeningeal treatment algorithm from “CSF cytology” to “CSF analysis” Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells alongside tumor-derived DNA and broaden the leptomeningeal treatment algorithm from “CSF cytology” to “CSF analysis”

[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranerse

Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely recognized standard in laboratory quality, sending shares of the Nasdaq-listed company up 8.7% to $5.89 Thursday. CNSide Diagnostics' Houston-based clinical laboratory underwent a rigorous on-site inspection evaluating clinical protocols, documentation, quality control procedures, personnel qualifications, equipment, facilities, and overall laboratory management.